Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial

Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial

Background: Quercetin, a natural polyphenol with demonstrated broad-spectrum antiviral, anti-inflammatory, and antioxidant properties, has been proposed as an adjuvant for early-stage coronavirus disease 2019 (COVID-19) infection.Objective: To explore the possible therapeutic effect of quercetin in...

Full description

Bibliographic Details
Main Authors: Francesco Di Pierro, Amjad Khan, Somia Iqtadar, Sami Ullah Mumtaz, Muhammad Nabeel Akbar Chaudhry, Alexander Bertuccioli, Giuseppe Derosa, Pamela Maffioli, Stefano Togni, Antonella Riva, Pietro Allegrini, Martino Recchia, Nicola Zerbinati
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Subjects:
Quercetin
COVID-19
SARS-CoV-2
Phytosome®
Natural Polyphenols
3CL protease inhibition
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1096853/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1096853/full

Similar Items